Recombinant human C1 esterase inhibitor treatment for hereditary angioedema attacks in children

Attacks of hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency (C1‐INH‐HAE) usually begin during childhood or adolescence. However, limited data are available regarding indications and modalities of treatment of children. This study evaluated recombinant human C1‐INH (rhC1‐INH) for HAE attacks in children.

[1]  H. Longhurst.  Optimum Use of Acute Treatments for Hereditary Angioedema: Evidence-Based Expert Consensus , 2018, Front. Med..

[2]  R. Lockey,et al.  The international WAO/EAACI guideline for the management of hereditary angioedema—The 2017 revision and update , 2018, Allergy.

[3]  M. Hutmacher,et al.  Exposure‐Response Model of Subcutaneous C1‐Inhibitor Concentrate to Estimate the Risk of Attacks in Patients With Hereditary Angioedema , 2018, CPT: pharmacometrics & systems pharmacology.

[4]  H. Farkas.  Pharmacological Management of Hereditary Angioedema with C1-Inhibitor Deficiency in Pediatric Patients , 2018, Pediatric Drugs.

[5]  W. Aberer,et al.  Treatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary Angioedema. , 2017, The journal of allergy and clinical immunology. In practice.

[6]  William H. Yang,et al.  Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial , 2017, The Lancet.

[7]  H. Farkas,et al.  The relationship between anxiety and quality of life in children with hereditary angioedema , 2017, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[8]  M. Riedl,et al.  Recombinant Human C1-Esterase Inhibitor to Treat Acute Hereditary Angioedema Attacks in Adolescents. , 2017, The journal of allergy and clinical immunology. In practice.

[9]  H. Farkas,et al.  Health‐related quality of life among children with hereditary angioedema , 2017, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[10]  M. Triggiani,et al.  International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency , 2016, Allergy.

[11]  B. Zuraw,et al.  Pediatric Hereditary Angioedema , 2016, Clinical pediatrics.

[12]  J. Skopál,et al.  Comprehensive study into the activation of the plasma enzyme systems during attacks of hereditary angioedema due to C1-inhibitor deficiency , 2015, Orphanet Journal of Rare Diseases.

[13]  T. Craig,et al.  Plasma‐derived C1‐INH for managing hereditary angioedema in pediatric patients: A systematic review , 2015, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[14]  J. Bernstein,et al.  Recombinant replacement therapy for hereditary angioedema due to C1 inhibitor deficiency. , 2015, Immunotherapy.

[15]  J. Bernstein,et al.  Recombinant human-C1 inhibitor is effective and safe for repeat hereditary angioedema attacks. , 2015, The journal of allergy and clinical immunology. In practice.

[16]  J. Bernstein,et al.  Clinical features of pediatric hereditary angioedema. , 2014, The journal of allergy and clinical immunology. In practice.

[17]  J. Bernstein,et al.  Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial. , 2014, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[18]  A. Gompel,et al.  Hereditary angioedema with C1 inhibitor deficiency: clinical presentation and quality of life of 193 French patients. , 2013, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[19]  M. Maurer,et al.  Hereditary angioedema with C1 inhibitor deficiency: delay in diagnosis in Europe , 2013, Allergy, Asthma & Clinical Immunology.

[20]  R. Tachdjian,et al.  Use of Ecallantide in Pediatric Hereditary Angioedema , 2013, Pediatrics.

[21]  J. Sheikh,et al.  A focused parameter update: hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor-associated angioedema. , 2013, The Journal of allergy and clinical immunology.

[22]  R. Lockey,et al.  Efficacy and safety of recombinant C1 inhibitor for the treatment of hereditary angioedema attacks: a North American open-label study. , 2013, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[23]  K. Bork,et al.  Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. , 2012, The Journal of allergy and clinical immunology.

[24]  M. Triggiani,et al.  Efficacy and safety of recombinant human C1‐inhibitor for the treatment of attacks of hereditary angioedema: European open‐label extension study , 2012, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[25]  J. Nuijens,et al.  Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. , 2010, The Journal of allergy and clinical immunology.

[26]  H. Farkas.  Pediatric hereditary angioedema due to C1-inhibitor deficiency. , 2010, Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology.

[27]  B. Zuraw.  Clinical practice. Hereditary angioedema. , 2008, The New England journal of medicine.

[28]  K. Bork,et al.  Hereditary angioedema: new findings concerning symptoms, affected organs, and course. , 2006, The American journal of medicine.

[29]  M. López-Trascasa,et al.  Hereditary angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain. , 2005, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[30]  M. Cicardi,et al.  Hereditary and Acquired C1‐Inhibitor Deficiency: Biological and Clinical Characteristics in 235 Patients , 1992, Medicine.

[31]  P. Harris,et al.  Koilonychia in Ladakhis , 1988, The British journal of dermatology.

[32]  M. Kerr,et al.  Cleavage of the second component of complement by plasma proteases: implications in hereditary C1-inhibitor deficiency. , 1985, Immunology.